OCULAR THERAPEUTIX, INC (OCUL) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $7.00M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $14.00M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $7.00M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $7.00M |
| Deferred revenue · latest quarter (USD) | $14.00M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | $931.00K | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $931.00K − $0.00 ≈ $931.00K |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 151.28M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 7.00M USD | Accounts Payable, Current |
| Total deferred revenue | 14.00M USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | (m) | Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Deferred revenue due after one year | 14.00M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | 931.00K USD | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability · Contract with Customer, Liability, Current · Deferred Revenue, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- $931.00K
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $6.59M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $7.00M | $14.00M | (m) | $931.00K | $151.28M | (m) | (m) | $14.00M | $931.00K | $0.00 |
| 2026-03-31 | (m) | $8.03M | $14.00M | (m) | $909.00K | $150.96M | (m) | (m) | $14.00M | $909.00K | $0.00 |
| 2025-12-31 | (m) | $4.15M | $14.00M | (m) | $887.00K | $153.75M | (m) | (m) | $14.00M | $887.00K | $0.00 |
| 2025-09-30 | (m) | $6.26M | $14.00M | (m) | $151.00K | $152.65M | (m) | (m) | $14.00M | $151.00K | $0.00 |
| 2025-06-30 | (m) | $5.89M | $14.00M | (m) | $148.00K | $145.42M | (m) | (m) | $14.00M | $148.00K | $0.00 |
| 2025-03-31 | (m) | $4.63M | $14.06M | (m) | $144.00K | $139.99M | (m) | $64.00K | $14.00M | $144.00K | $0.00 |
| 2024-12-31 | (m) | $4.18M | $14.13M | (m) | $141.00K | $142.59M | (m) | $128.00K | $14.00M | $141.00K | $0.00 |
| 2024-09-30 | (m) | $4.00M | $14.19M | (m) | $117.00K | $138.35M | (m) | $190.00K | $14.00M | $117.00K | $0.00 |
| 2024-06-30 | (m) | $3.69M | $14.27M | (m) | $114.00K | $139.40M | (m) | $269.00K | $14.00M | $114.00K | $0.00 |
| 2024-03-31 | (m) | $6.45M | $14.33M | (m) | $111.00K | $130.96M | (m) | $263.00K | $14.07M | $111.00K | $0.00 |
| 2023-12-31 | (m) | $4.39M | $14.39M | (m) | $108.00K | $160.93M | (m) | $255.00K | $14.13M | $108.00K | $0.00 |
| 2023-09-30 | (m) | $3.98M | $14.51M | (m) | $106.00K | $154.53M | (m) | $317.00K | $14.20M | $106.00K | $0.00 |
| 2023-06-30 | (m) | $3.57M | $14.64M | (m) | $104.00K | $119.47M | (m) | $391.00K | $14.25M | $104.00K | $0.00 |
| 2023-03-31 | (m) | $5.44M | $13.80M | (m) | $100.00K | $118.86M | (m) | $463.00K | $13.34M | $100.00K | $0.00 |
| 2022-12-31 | (m) | $5.12M | $13.96M | (m) | $93.00K | $113.91M | (m) | $576.00K | $13.39M | $93.00K | $0.00 |
| 2022-09-30 | (m) | $5.31M | $14.14M | (m) | (m) | $112.35M | (m) | $603.00K | $13.53M | (m) | $0.00 |
| 2022-06-30 | (m) | $3.70M | $14.19M | (m) | (m) | $107.27M | (m) | $1.19M | $13.00M | (m) | $0.00 |
| 2022-03-31 | (m) | $3.42M | $14.31M | (m) | (m) | $107.83M | (m) | $1.21M | $13.10M | (m) | $0.00 |
| 2021-12-31 | (m) | $4.59M | (m) | (m) | (m) | $116.89M | (m) | (m) | $13.00M | (m) | $0.00 |
| 2021-09-30 | (m) | $4.25M | (m) | (m) | (m) | $130.40M | (m) | (m) | $12.00M | (m) | $0.00 |
| 2021-06-30 | (m) | $3.88M | (m) | (m) | (m) | $150.46M | (m) | (m) | $12.00M | (m) | $0.00 |
| 2021-03-31 | (m) | $4.15M | (m) | (m) | (m) | $159.63M | (m) | (m) | $12.00M | (m) | $0.00 |
| 2020-12-31 | (m) | $2.71M | (m) | (m) | (m) | $185.77M | (m) | (m) | $12.00M | (m) | $0.00 |
| 2020-09-30 | (m) | $3.24M | (m) | (m) | (m) | $102.34M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.65M | (m) | (m) | (m) | $101.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $2.84M | (m) | (m) | (m) | $83.52M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.27M | (m) | (m) | (m) | $82.37M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $3.46M | (m) | (m) | (m) | $77.41M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $4.04M | (m) | (m) | (m) | $81.48M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.90M | (m) | (m) | (m) | $75.84M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.96M | (m) | (m) | (m) | $37.17M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.78M | (m) | (m) | (m) | $24.75M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.14M | (m) | (m) | (m) | $24.73M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $3.48M | (m) | (m) | (m) | $27.50M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.57M | (m) | (m) | (m) | $29.28M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.60M | (m) | (m) | (m) | $28.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $6.31M | (m) | (m) | (m) | $31.65M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.75M | (m) | (m) | (m) | $26.79M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.12M | (m) | (m) | (m) | $22.93M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $1.68M | (m) | (m) | (m) | $20.05M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $1.61M | (m) | (m) | (m) | $19.45M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.06M | (m) | (m) | (m) | $20.26M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.96M | (m) | (m) | (m) | $20.72M | (m) | $42.00K | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.62M | (m) | (m) | (m) | $20.51M | (m) | $83.00K | (m) | (m) | (m) |
| 2015-06-30 | (m) | $2.81M | (m) | (m) | (m) | $20.36M | (m) | $125.00K | (m) | (m) | (m) |
| 2015-03-31 | (m) | $2.19M | (m) | (m) | (m) | $19.42M | (m) | $250.00K | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.32M | (m) | (m) | (m) | $19.50M | (m) | $188.00K | (m) | (m) | (m) |
| 2014-09-30 | (m) | $649.00K | (m) | (m) | (m) | $18.28M | (m) | $250.00K | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.52M | (m) | (m) | (m) | $19.05M | (m) | $250.00K | (m) | (m) | (m) |
| 2013-12-31 | (m) | $545.00K | (m) | (m) | (m) | $4.27M | (m) | $250.00K | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |